ATE428781T1 - Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose - Google Patents

Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Info

Publication number
ATE428781T1
ATE428781T1 AT02767738T AT02767738T ATE428781T1 AT E428781 T1 ATE428781 T1 AT E428781T1 AT 02767738 T AT02767738 T AT 02767738T AT 02767738 T AT02767738 T AT 02767738T AT E428781 T1 ATE428781 T1 AT E428781T1
Authority
AT
Austria
Prior art keywords
bases
nebularine
hypoxanthine
combinations
uracil
Prior art date
Application number
AT02767738T
Other languages
English (en)
Inventor
Nigel Phillips
Mario Filion
Zdenek Holan
Reader Stephanie Dr
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE428781T1 publication Critical patent/ATE428781T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
AT02767738T 2001-08-17 2002-08-19 Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose ATE428781T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31329001P 2001-08-17 2001-08-17
PCT/IB2002/003323 WO2003016528A2 (en) 2001-08-17 2002-08-19 Oligonucleotide compositions and their use to induce apoptosis

Publications (1)

Publication Number Publication Date
ATE428781T1 true ATE428781T1 (de) 2009-05-15

Family

ID=23215136

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02767738T ATE428781T1 (de) 2001-08-17 2002-08-19 Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
AT02760451T ATE325341T1 (de) 2001-08-17 2002-08-19 Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02760451T ATE325341T1 (de) 2001-08-17 2002-08-19 Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden

Country Status (14)

Country Link
US (5) US7200531B2 (de)
EP (2) EP1448986B1 (de)
JP (2) JP4504015B2 (de)
KR (2) KR100943567B1 (de)
AT (2) ATE428781T1 (de)
AU (2) AU2002330663B2 (de)
CA (2) CA2457783A1 (de)
DE (2) DE60231986D1 (de)
DK (1) DK1417307T3 (de)
ES (1) ES2325247T3 (de)
HK (1) HK1069205A1 (de)
IL (4) IL160407A0 (de)
MX (2) MXPA04001315A (de)
WO (2) WO2003016528A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074342A2 (en) * 2000-03-31 2001-10-11 Trustees Of Boston University Use of locally applied dna fragments
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
ATE428781T1 (de) * 2001-08-17 2009-05-15 Bioniche Life Sciences Inc Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
WO2004014312A2 (en) * 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
US20060269924A1 (en) * 2003-04-11 2006-11-30 Trustees Of Boston University Modulation of telomere-initiated cell signaling
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
CN102791291A (zh) * 2009-11-10 2012-11-21 拜昂尼科生命科学有限公司 含有非dna碱基的多核苷酸组合物和其用于调节免疫反应的用途
CN106709925A (zh) * 2016-12-30 2017-05-24 上海联影医疗科技有限公司 医学图像中椎块的定位方法及其装置
CN107704697B (zh) * 2017-10-18 2019-08-20 西南交通大学 一种型材三维拉弯成形性预测评价优化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106727A (en) * 1989-04-27 1992-04-21 Life Technologies, Inc. Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers
WO1993018187A1 (en) * 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
DK0805876T3 (da) * 1995-01-19 2000-11-06 Gen Probe Inc Nukleinsyreamplifikationsoligonukleotider og prober til Lyme-sygdom-associeret Borrelia
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
EP1171634B1 (de) * 1999-04-08 2005-10-26 Gen-Probe Incorporated Amplifikation und sequenzierung von primer-paaren und deren verwendung
HUP0300627A3 (en) * 1999-12-13 2005-11-28 Bioniche Life Sciences Inc Bel Therapeutically useful synthetic oligonucleotides
WO2003070888A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
ATE428781T1 (de) * 2001-08-17 2009-05-15 Bioniche Life Sciences Inc Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Also Published As

Publication number Publication date
US8350016B2 (en) 2013-01-08
JP4504015B2 (ja) 2010-07-14
WO2003016528A3 (en) 2003-10-09
US20080077372A1 (en) 2008-03-27
EP1417307B1 (de) 2009-04-15
EP1448986A2 (de) 2004-08-25
AU2002326067B2 (en) 2007-05-31
JP4469603B2 (ja) 2010-05-26
JP2005521119A (ja) 2005-07-14
JP2005509411A (ja) 2005-04-14
IL160408A0 (en) 2004-07-25
IL160407A (en) 2010-02-17
ATE325341T1 (de) 2006-06-15
WO2003016567A2 (en) 2003-02-27
US7199228B2 (en) 2007-04-03
US20030144233A1 (en) 2003-07-31
IL160408A (en) 2010-05-31
US20080081793A1 (en) 2008-04-03
KR101017483B1 (ko) 2011-02-25
US20030113763A1 (en) 2003-06-19
DE60211206T2 (de) 2006-10-26
KR20040032925A (ko) 2004-04-17
ES2325247T3 (es) 2009-08-31
AU2002330663B2 (en) 2007-09-20
WO2003016528A2 (en) 2003-02-27
KR20040030138A (ko) 2004-04-08
DE60231986D1 (de) 2009-05-28
DK1417307T3 (da) 2009-07-13
IL160407A0 (en) 2004-07-25
WO2003016567A3 (en) 2004-06-03
MXPA04001315A (es) 2004-05-20
US20110160291A1 (en) 2011-06-30
US7893242B2 (en) 2011-02-22
CA2457789A1 (en) 2003-02-27
HK1069205A1 (en) 2005-05-13
EP1448986B1 (de) 2006-05-03
EP1417307A2 (de) 2004-05-12
CA2457783A1 (en) 2003-02-27
US7200531B2 (en) 2007-04-03
MXPA04001480A (es) 2004-05-20
KR100943567B1 (ko) 2010-02-22
DE60211206D1 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
HK1069205A1 (en) Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
ES2118593T3 (es) Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
AR019011A1 (es) Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich
ES2235353T3 (es) Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BR9709443B1 (pt) n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
IL173888A0 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
ATE505474T1 (de) Inhibitoren von nukleosidphosphorylasen und nukleosidasen
ECSP055561A (es) Procesos para la preparación de pirimidinas sustituidas y derivados de pirimidina como inhibidores de las proteínas quinasas
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
DK0988301T3 (da) Imidazolylcykliske acetaler
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
BR9811805A (pt) Derivados quinazolina substituìda e seu uso como inibidores de quinase tirosina
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DK1045690T3 (da) Benzensulfonamidinhibitorer af PDE-IV og deres terapeutiske anvendelse
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
BR0315689A (pt) Alvo para terapia de dano cognitivo
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
TR200200278T2 (tr) Kalsilitik bileşimler
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1417307

Country of ref document: EP